title: Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease.
abstract: OBJECTIVE
  We evaluated microRNAs (miRNAs) as potential biomarkers for Alzheimer disease (AD) by analyzing the expression level of miRNAs in CSF of patients with AD dementia and nonaffected control subjects.
  
  
  METHODS
  Using quantitative PCR, we profiled the expression level of 728 miRNAs in CSF of nonaffected control subjects and patients with clinically ascertained AD dementia, and we further compared the expression level of candidate miRNAs in 37 control subjects and 35 patients with AD dementia.
  
  
  RESULTS
  The level of hsa-miR-27a-3p in CSF is reduced in patients with dementia due to AD in 2 different cohorts of subjects (cohort 1: p = 0.008; cohort 2: p = 0.015; 2-tailed unpaired Welch t test). Moreover, low levels of hsa-miR-27a-3p were accompanied by high CSF tau levels and low CSF β-amyloid levels.
  
  
  CONCLUSIONS
  Our pilot study highlights hsa-miR-27a-3p as a candidate biomarker for AD and provides the groundwork for further confirmation studies in larger cohorts and in other hospitals.
authors.affiliation: From the VIB Center for the Biology of Disease (C.S.F., P.L., E.S., B.D.S.), Leuven; Center for Human Genetics and LIND (C.S.F., P.L., E.S., B.D.S.), and Alzheimer Research Centre KU Leuven, Leuven Institute for Neuroscience and Disease (R.V.), University of Leuven; Geriatric Medicine (J.T.), and Neurology Department (R.V.), University Hospitals Leuven; Department of Clinical and Experimental Medicine and LIND (J.T.), Laboratory for Cognitive Neurology, Department of Neurosciences (R.V.), KU Leuven, Belgium; Netherlands Institute for Neuroscience (K.B.), Amsterdam, the Netherlands; Clinical Neurochemistry Laboratory (A.W., M.B., H.Z., K.B.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
authors.forename: Carlo
authors.initials: C
authors.lastname: Sala Frigerio
authors.forename: Pierre
authors.initials: P
authors.lastname: Lau
authors.forename: Evgenia
authors.initials: E
authors.lastname: Salta
authors.forename: Jos
authors.initials: J
authors.lastname: Tournoy
authors.forename: Koen
authors.initials: K
authors.lastname: Bossers
authors.forename: Rik
authors.initials: R
authors.lastname: Vandenberghe
authors.forename: Anders
authors.initials: A
authors.lastname: Wallin
authors.forename: Maria
authors.initials: M
authors.lastname: Bjerke
authors.forename: Henrik
authors.initials: H
authors.lastname: Zetterberg
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.forename: Bart
authors.initials: B
authors.lastname: De Strooper
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000175:diagnosis / Q000378:metabolism; D015415:Biomarkers / Q000134:cerebrospinal fluid; D015331:Cohort Studies; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000134:cerebrospinal fluid*; D008875:Middle Aged; D010865:Pilot Projects
chemical_list: D015415:Biomarkers; C531388:MIRN27 microRNA, human; D035683:MicroRNAs